
Untreated
Live VSV
NRRPs
Leukemia
Jurkat
A20
A301
HL60
Normal
HDF
GM38

Fig. 6

Fig. 8C


PBS
NRRPs
Late Apoptosis
4%
Late Apoptosis
35%
Viable
89%
Early Apoptosis
7%
Viable
16%
Early Apoptosis
49%
7-AAD
AnnexinV-APC

Fig. 9


Viability (%)
PBS
Bendamustine (300uM)
NRRP (particle to cell ratio)

Fig. 10


120
100
80
60
40
20
0
Viability (%)
PBS
Dexamethasone (45uM)
1
10
100
1000
NRRP (particle to cell ratio)

Fig. 11


120
100
80
60
40
20
0
Viability (%)
PBS
Doxorubicin (0.025uM)
0.1
1
10
100
1000
NRRP (particle to cell ratio)

Fig. 12


120
100
80
60
40
20
0
Viability (%)
PBS
Vincristine (0.0125uM)
0.1
1
10
100
1000
NRRP (particle to cell ratio)

Fig. 13


120
100
80
60
40
20
0
Viability (%)
PBS
Idarubicin (0.05uM)
0.1
1
10
100
1000
NRRP (particle to cell ratio)

Fig. 14



Fig. 15A



Fig. 15B



Fig. 15C



Fig. 15D



Fig. 16A


Untreated
Live VSV
NRRPs
Patient 1
Patient 2
1000µm
1000µm
1000µm
1000µm
1000µm
1000µm

Fig. 16B



Fig. 16C



Fig. 16D



Fig. 17A



Fig. 17B



Fig. 18A



Fig. 18B


100
75
50
25
0
Survival (%)
10
20
30
40
Day
Cells
Cells+NRRPs

Fig. 19


MM (MCP-11)
PBS
NRRPs
MM (RPMI-8226)
PBS
NRRPs

Fig. 20


120
100
80
60
40
20
0
Viability (%)
RPMI8226
SR4987
MPC-11
0.1
1
10
100
1000
MOI

Fig. 21


120
100
80
60
40
20
0
Viability (%)
PBS
Melphalan (20uM)
0.1
1
10
100
1000
NRRP (particle to cell ratio)

Fig. 22


120
100
80
60
40
20
0
Viability (%)
PBS
LCL161 (15uM)
1
10
100
1000
NRRP (particle to cell ratio)

Fig. 23


120
100
80
60
40
20
0
Viability (%)
Carfilzomib
PBS
0.1
1
10
100
1000
10000
NRRP (particle to cell ratio)

Fig. 24

DBT



PBS **NRRPs**

Fig. 25A

K1491



PBS **NRRPs**

Fig. 25B

GL261



PBS **NRRPs**

Fig. 25C


140
120
100
80
60
40
20
0
Viability (%)
HDFN (normal)
GL261
CT2A
DBT
K1492
K1491
1
10
100
1000
NRRP (particle to cell ratio)

Fig. 26


120
100
80
60
40
20
0
Viability (%)
PBS
SAHA (10uM)
1
10
100
1000
NRRP (particle to cell ratio)

Fig. 27



Fig. 28A



Fig. 28B



Fig. 28C



Fig. 29